U.S. Markets open in 8 hrs.

Elanix Biotechnologies AG (ELN.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
5.132-0.014 (-0.272%)
At close: 5:36PM CEST

Elanix Biotechnologies AG

Tomas Svoboda (Vorstand)
Domstrasse, 22
Potsdam 14482
49 331 74 00 804

Full Time Employees5

Key Executives

Mr. Richard PajerVice-Chairman of the Supervisory Board and Member of the Management BoardN/AN/AN/A
Mr. Armin SchulzMember of the Management BoardN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Elanix Biotechnologies AG develops and commercializes products for acute wound care, and dermatological and gynecological applications. The company develops and markets progenitor cell-based products that are used to regenerate tissue and promote healing in the treatment of burns, and gynecological and dermatological conditions. Its products include GYNrepair, a cream for genital external mucosa; and SKINrepair, a cream for skin that protects against external aggressions. The company is also developing FirstCover, an acute wound care tissue engineering product that is used to provide protection and healing for burns, and trauma and plastic surgery. In addition, it offers cell technology services. The company was formerly known as Porta Systems AG and changed its name to Elanix Biotechnologies AG in December 2015. Elanix Biotechnologies AG is based in Potsdam, Germany.

Corporate Governance

Elanix Biotechnologies AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.